Synchronous immune alterations mirror clinical response during allergen immunotherapy

Amedee Renand, Mohamed H. Shamji, Kristina M. Harris, Tielin Qin, Erik Wambre, Guy W. Scadding, Peter A. Wurtzen, Stephen J. Till, Alkis Togias, Gerald T. Nepom, William W. Kwok, Stephen R. Durham

Research output: Contribution to journalArticlepeer-review

65 Scopus citations

Abstract

Background: Three years of treatment with either sublingual or subcutaneous allergen immunotherapy has been shown to be effective and to induce long-term tolerance. The Gauging Response in Allergic Rhinitis to Sublingual and Subcutaneous Immunotherapy (GRASS) trial demonstrated that 2 years of treatment through either route was effective in suppressing the response to nasal allergen challenge, although it was insufficient for inhibition 1 year after discontinuation. Objective: We sought to examine in the GRASS trial the time course of immunologic changes during 2 years of sublingual and subcutaneous immunotherapy and for 1 year after treatment discontinuation. Methods: We performed multimodal immunomonitoring to assess allergen-specific CD4 T-cell properties in parallel with analysis of local mucosal cytokine responses induced by nasal allergen exposure and humoral immune responses that included IgE-dependent basophil activation and measurement of serum inhibitory activity for allergen-IgE binding to B cells (IgE-facilitated allergen binding). Results: All 3 of these distinct arms of the immune response displayed significant and coordinate alterations during 2 years of allergen desensitization, followed by reversal at 3 years, reflecting a lack of a durable immunologic effect. Although frequencies of antigen-specific T H 2 cells in peripheral blood determined by using HLA class II tetramer analysis most closely paralleled clinical outcomes, IgE antibody–dependent functional assays remained inhibited in part 1 year after discontinuation. Conclusion: Two years of allergen immunotherapy were effective but insufficient for long-term tolerance. Allergen-specific T H 2 cells most closely paralleled the transient clinical outcome, and it is likely that recurrence of the T-cell drivers of allergic immunity abrogated the potential for durable tolerance. On the other hand, the persistence of IgE blocking antibody 1 year after discontinuation might be an early indicator of a protolerogenic mechanism.

Original languageEnglish
Pages (from-to)1750-1760.e1
JournalJournal of Allergy and Clinical Immunology
Volume141
Issue number5
DOIs
StatePublished - May 2018
Externally publishedYes

Keywords

  • Allergy
  • T 2 cells
  • allergen desensitization
  • immune tolerance
  • immunotherapy

Fingerprint

Dive into the research topics of 'Synchronous immune alterations mirror clinical response during allergen immunotherapy'. Together they form a unique fingerprint.

Cite this